Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference

Rhea-AI Summary

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for women’s cancers, announced the participation of its President and CEO, Sean Bohen, in a panel discussion on “ER+/HER2- Breast Cancer” at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference. This event is scheduled for April 20, 2023, at 2:00 p.m. ET.

Olema's lead product candidate, OP-1250, is an innovative treatment designed as both a complete estrogen receptor antagonist and a selective estrogen receptor degrader. Currently in a Phase 2 clinical trial, OP-1250 is being assessed as a single agent and in combination with existing therapies for patients with recurrent advanced ER-positive, HER2-negative breast cancer. The FDA has granted it Fast Track designation for treating metastatic cases that have failed prior endocrine therapies.

SAN FRANCISCO, April 13, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on “ER+/HER2- Breast Cancer” at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on Thursday, April 20, 2023, at 2:00 p.m. ET.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

IR Contact:
Shane Kovacs, Chief Operating and Financial Officer
ir@olema.com

Media Contact:
Ignacio Guerrero-Ros, Ph.D., Russo Partners
646-942-5604
ignacio.guerrero-ros@russopartnersllc.com

FAQ

When is Olema's panel discussion on ER+/HER2- Breast Cancer scheduled?

Olema Pharmaceuticals' panel discussion is scheduled for April 20, 2023, at 2:00 p.m. ET.

What is OP-1250 and its significance in breast cancer treatment?

OP-1250 is Olema's lead product candidate, functioning as both a complete estrogen receptor antagonist and selective estrogen receptor degrader, currently undergoing Phase 2 trials.

Has OP-1250 received any special designations from the FDA?

Yes, OP-1250 has been granted FDA Fast Track designation for treating ER+/HER2- metastatic breast cancer that has progressed after endocrine therapy.

What type of cancer does Olema Pharmaceuticals focus on?

Olema Pharmaceuticals focuses on women's cancers, specifically developing targeted therapies.

Where is Olema Pharmaceuticals headquartered?

Olema Pharmaceuticals is headquartered in San Francisco, with additional operations in Cambridge, Massachusetts.